Recombinant RSV (Felvizumab Biosimilar) 抗体
This anti-RSV (Felvizumab Biosimilar) antibody is a Human 单克隆 antibody detecting RSV (Felvizumab Biosimilar) in ELISA 和 Func. Suitable for Respiratory Syncytial Virus (RSV).
Quick Overview for Recombinant RSV (Felvizumab Biosimilar) 抗体 (ABIN5668206)
抗原
RSV (Felvizumab Biosimilar)
抗体类型
Recombinant Antibody
适用
Respiratory Syncytial Virus (RSV)
宿主
Human
克隆类型
单克隆
标记
This RSV (Felvizumab Biosimilar) antibody is un-conjugated
应用范围
ELISA, Functional Studies (Func)
克隆位点
RSHZ19
-
-
原理
- Anti-RSV [RSHZ19 (Felvizumab)], Human IgG1, kappa
-
特异性
- This antibody is specific for the an epitope located between amino acids 417-432 of conserved fusion (F) protein of RSV.
-
产品特性
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
纯化方法
- Protein A affinity purified
-
纯度
- > 98 % as determined by SDS-PAGE
-
内毒素水平
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
-
免疫原
- This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.
-
亚型
- IgG1 kappa
-
-
-
-
应用备注
- Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).
-
限制
- 仅限研究用
-
-
-
浓度
- 1 mg/mL
-
缓冲液
- PBS with 0.02 % Proclin 300.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- RSV (Felvizumab Biosimilar)
-
物质类
- Biosimilar
-
背景
- SB 209763, respiratory syncytial virus
抗原
-
You are here:
